Roth starts Intellipharmaceutics at buy

Roth Capital Partners has initiated coverage of Intellipharmaceutics (NASDAQ:IPCI; TSX:I) with a “buy” rating and 12-month price target of $5.25, saying the emerging generics company could launch four new products in the coming 12-to-18 months. “We believe that this momentum could unlock value for this under covered stock,” writes analyst Scott Henry. The stock closed [...]

Roth starts TearLab at buy

Roth Capital Partners has initiated coverage of TearLab (NASDAQ:TEAR; TSX:TLB) with the “buy” rating and 12-month price target of $2.20. The stock was quoted at $1.42, up 12%, Thursday morning. Analyst Matt Dolan writes that he expects company’s sales to “ramp steadily over the next several quarters, with the potential for a more substantial acceleration [...]

Roth adds Synovis to focus list

Roth Capital Partners has added Synovis Life Technologies (NASDAQ:SYNO) to its Med Tech “focus list” after last week’s market volatility brought the stock down about 14% from recent highs. The stock finished last week at $16.48. Analyst Matt Dolan rates Synovis a “buy,” with a 12-month price target of $21. “In volatile market conditions, we [...]

Roth ups AtriCure target to $15

Roth Capital Partners has raised its target price on AtriCure (NASDAQ:ATRC) to $15 from $13.50, heading into the company’s FDA advisory panel meeting. The stock was quoted at $11.80 Monday afternoon. “While FDA panel votes are difficult to predict, we view AtriCure’s risk-reward as positive and believe a positive recommendation would have major strategic implications [...]

Roth sees buying opportunity in Pharmacyclics decision

Pharmacyclics (NASDAQ:PCYC) is suspending preclinical development of its follow on Btk inhibitor, PCI-45292, for autoimmune disorders because of an unfavorable result in a toxicology study. It expects to have a new candidate ready in about six months. In a research note, Roth Capital analyst Joseph Pantginis writes that the unexpected development represents a “compelling buying opportunity.” [...]

Medicago offers $7 million of units

Medicago (TSX:MDG) has entered into an agency agreement and carried out an overnight marketed offering to sell up to 17,283,952 units at a price of 40.5 cents each in order to finance its $7.5 million share of a new U.S. pandemic vaccine plant that includes a grant from an arm of the U.S. Department of [...]